

CURRICULUM VITAE

Kalomenidis Ioannis (John)

**PULMONARY PHYSICIAN
ASSOCIATE PROFESSOR**

PERSONAL DATA

NAME: Kalomenidis Ioannis (John)
BIRTHPLACE: Kavala, Greece
DATE OF BIRTH: 14 June, 1967
NATIONALITY: Greek
MARITAL STATUS: Married with one child
LANGUAGES: Greek, English
ADDRESS:
Work: 1st Department of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece
45-47 Ipsilandou str, Athens, Greece.
Tel: ++30 210 7201913
e-mail: ikalom@med.uoa.gr
Home: 5 Pentelis str, 15126, Marousi, Greece

CURRENT POSITION

Associate Professor and Consultant, 1st Department of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece.

PROFESSIONAL TITLES:

- *Medical Doctor (MD)*, University of Thrace Medical School, Alexandroupolis, Greece (1991)
- *Specialist title in Pulmonary Medicine. Athens, Greece* (1996)
- *Doctor of Philosophy (PhD)*, University of Athens Medical School (1999). Thesis: “Prospective study of p53 tumor suppressor gene and K-ras oncogene mutations in bronchial biopsies obtained during fiberoptic bronchoscopy from patients with primary lung cancer”.

PROFESSIONAL POSITIONS:

- December 1991 – December 1992 : Resident, 2nd Department of Internal Medicine, Kavala General Hospital, Kavala, Greece
- February – May 1993: Resident, 2nd Department of Pulmonary Medicine, Kavala General Hospital, Kavala, Greece.
- May 1993 – February 1996 : Resident, Department of Respiratory Medicine, University of Athens Medical School, Sotiria Chest Hospital, Athens, Greece.
- March– July 1996: Medical Coordinator, Medicine de Monde, Tbilisi, Georgia.
- November 1996 - August 1997: Primary Care Physician, Greek Army.
- Sep. 1997 - May 1998: Attending Physician, Pulmonary Department, 401 General Army Hospital, Athens, Greece.
- June 1998 – July 1999: Fellow, Intensive Care Unit, Nice District General Hospital, Piraeus, Greece.
- March 2000 – January 2002: Consultant, Department of Critical Care and Pulmonary Services, University of Athens Medical School, Evangelismos Hospital, Athens, Greece.
- February 2002 – January 2003: Research fellow in Dr Richard W Light’s group, Department of Pulmonary and Critical Care Medicine, Vanderbilt University and St Thomas Hospital, Nashville, TN, USA.
- February 2003 – March 2006: Consultant, 1st Department of Critical Care and Pulmonary Services, University of Athens Medical School, Evangelismos Hospital, Athens, Greece.
- March 2006 – August 2010: Lecturer and Consultant, 2nd Pulmonary Department, Attikon Hospital, National and Kapodistrian University of Athens.

- August 2010 – July 2012: Assistant Professor and Consultant, 2nd Pulmonary Department, Attikon Hospital, National and Kapodistrian University of Athens.
- February 2012 – March 2012. Visiting Professor with honorary contract. Southmead Hospital, University of Bristol, Bristol, UK.
- August 2012 – June 2016: Assistant Professor and Consultant, 1st Department of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital.
- June 2016 – today: Associate Professor and Consultant, 1st Department of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital. Head of the Pulmonary Clinic.

TEACHING EXPERIENCE

- *Supervision of Ph.D. Projects*

1. Ioannis Psallidas, MD. The role of osteopontin in malignant pleural effusions. mesothelioma. A preclinical study. Athens 2012.
2. Chrysoula Kairi, MD. Preclinical study of therapeutic blockage of MCP-1/5 in a murine model of malignant pleural effusion. Athens 2014.
3. Kostantinos Doris, MD. Experimental study of the impact of airway allergic inflammation in chemical lung carcinogenesis. Athens 2014.
4. Maria Eleni Vazakidou, MSc. Role of mTOR in of malignant pleural mesothelioma. Therapeutic potential. Athens 2015.
5. Kypariso Karabela, MSc. Therapeutic inhibition of the NF-κB pathway in an experimental model of chemical lung carcinogenesis. Athens 2016.
6. Ourania Kotsiou. Determination of the concentration of alarmin HMGB1 and IL33 and their receptors, sRAGEs and sST2 in the pleural fluid of patients with pleural effusions. Larisa 2018.
7. Dimitra Kerdinani, MSc. Role of WNT proteins in NSCLC immune evasion. Athens 2019.
8. Marianthi Iliopoulou, MD. Microbiology of pleural infection in Greece. Ongoing.
9. Apostolos Papas, MD. Role of Versican in pleural malignancies. Ongoing.
10. Charalampos Moschos, MD. Ongoing.
11. Chrysavgi Kosti. Role of CSF1R in malignant pleural effusion. Ongoing.
12. Stavros Theologou. Oxygen therapy in cardiosurgery patients. Ongoing
13. Spyridon Ladias. Role of ADA and IL-17 in diagnosis and prognosis of patients with malignant pleural effusions. Ongoing
14. Athanasia. Papalampidou. Role of high-flow oxygen in COPD treatment. Ongoing
15. Marios Ioannou. Role of add-on tiotropium bromide treatment on ex- or current smokers with asthma. Ongoing
16. Nikolaos Vihos. Etiology of severe asthma exacerbations. Ongoing

- *Supervision Master Theses*

1. Eleni Flountzi. Factors predicting malignancy in diagnostic thoracoscopy. Athens 2013.
2. Kostantinos Eleftheriou. Prevalence, diagnosis and prognostic significance of pleural invasion in patients with lung cancer. Athens 2018.
3. Lambrini Tina. Study of sleep quality of students of nursing school. Athens 2019.
4. Matheos Vlachos. Rehabilitation at IPF. Athens 2019.

- *Undergraduate and Post-graduate Teaching*

- Clinical training and lectures for undergraduate students at the following departments of the University of Athens School of Medicine: 1st Department of Critical Care and Pulmonary Medicine, the 2nd Department of Pulmonary Medicine and the 2nd Department of Internal Medicine (2004-2012).
- Lecture on the Respiratory Pathophysiology, for undergraduate students at the Department of Dietics and Nutritional Science, Harokopeion University (2013-2018).
- Contribution with lectures and practical training in ICU training program for nurses. “Ag. Panteleimon General Hospital” (1998-99).
- Contribution with lectures in the residents' educational program of the following departments: Department of Pulmonary Medicine, 401 Athens General Army Hospital (1997-98), 5th Department of Internal Medicine, Evangelismos Hospital (2004-6 and 2012) and the 2nd Department of Internal Medicine, Athens University School of Medicine, Attikon Hospital (2007-8), 1st Department of

Surgery, Evangelismos Hospital (2012), 4th and 10th Pulmonary Department, Sotiria Hospital (2015), Pulmonary Department, University Hospital of Larisa (2015, 2016), 2nd Pulmonary Department, Sismanoglio Hospital (2016).

- Contribution with lectures for ICU Fellows, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, Athens University School of Medicine (2012- today).
- Contribution with lectures at the post-graduate seminar of the 2nd Department of Radiology, University of Athens School of Medicine (2005-6).
- Contribution with lectures on pleural disease in the Athens University School of Medicine/Hellenic Thoracic Society post-graduate seminars “Continuous education in Respiratory Medicine” (2005-2012).
- Contribution with lectures on several aspects of pleural diseases in the post-graduate seminars of the 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, Athens University School of Medicine (2003-2006).
- Contribution with lectures on pleural diseases in the Refreshing Courses for Pulmonary Fellows organized by the Hellenic Thoracic Society (2008, 2009, 2011-13, 2014-15, 2015-16).
- Member of the organizing committee of the post-graduate seminars of the 1st Department of Critical Care and Pulmonary Medicine of Athens University School of Medicine (2005-2010).
- Member of the organizing committee of the Refreshing Courses for Pulmonary Fellows organized by the Hellenic Thoracic Society (2012).

Teaching in Master Programs

- Contribution with lectures in the Master Program “ICU and Emergency Medicine” of Athens University School of Medicine for nurses (2014-15, 2015-16, 2017-18, 2018-19).
- Contribution with a lecture in the Master Program “Sleep-related Respiratory disorders. Clinical and Laboratory Sleep Medicine” of Athens University School of Medicine (2017).
- Contribution at the Master Program “Ageing and Chronic Diseases” of the Hellenic Open University. Subject: Physiology (2016-17, 2017-18, 2019-20).
- Contribution with a lecture in the Master Program “Cardiopulmonary rehabilitation and rehabilitation of critically ill patients” of Athens University School of Medicine (2017-18, 2018-19).
- Contribution with lectures in the Master Program “Respiratory Failure and Mechanical Ventilation” of Athens University School of Medicine (2018-19, 2019-20).

AWARDS

1. Best experimental study. D Orphanidou, **I Kalomenidis**, G Papamichalis, A Rasidakis, M Toumbis, I Lampaditis, I Papastamatiou, J Jordanglou. p53 expression in neoplastic, preneoplastic and normal bronchial mucosa. 8th Annual Congress of the Hellenic Thoracic Society. Athens 1996
2. Best Poster in Category Award. Y Guo, **I Kalomenidis**, M Hawthorne, KB Lane, RW Light. The effect of anti-Vascular Endothelial Growth Factor antibody on pleurodesis induced by Transforming Growth Factor-beta in rabbits. CHEST 2003, October 25-30 2003, Orlando, USA
3. Best abstract on lung cancer. GT Stathopoulos, W Han, **I Kalomenidis**, A Kollintza, T Sherrill, M Karatza, S Vasiliou, C Roussos, B Fingleton, F Yull, T Blackwell. Experimental, urethan-induced lung carcinogenesis is associated with the inflammatory response and NfkappaB activation. 14th Annual Congress of the Hellenic Thoracic Society. December 1-4 2005, Thessaloniki, Greece.
4. G Stathopoulos, **I Kalomenidis**. Commendation for outstanding abstract. 10th State-of -the-Art Interdisciplinary Review Course on Pulmonary Diseases, Critical Care, Emergency Medicine, and Nursing Care, April 6-9 2006, Athens, Greece.
5. 2nd Best Basic Science Abstract. GT Stathopoulos, T Sherrill, **I Kalomenidis**, PR Stokes, TS Blackwell. IL-5 promotes experimental tumors. 32nd Annual Hellenic National Medical Congress, May 9-13 2006, Athens, Greece.
6. 3d Best Study Award. GT Stathopoulos, A Kollintza, C Moschos, I Psallidas, T Sherril, E Pitsinos, S Vasiliou, M Karatza, S Papiris, D Graf, D Orphanidou, RW Light, C Roussos, TS Blackwell, **I Kalomenidis**. Tumor-derived TNFalpha is sufficient for promotion of experimental malignant pleural effusion through NFKappaB activation, apoptosis down-regulation and enhancement of VEGF expression, angiogenesis and vascular permeability. 15th Annual Congress of the Hellenic Thoracic Society. November 2-5 2006, Iraklion, Greece
7. 3d Best Study Award. GT Stathopoulos, C Moschos, A Kollintza, I Psallidas, A Moustaki, I Petroheilou, P Theodoropoulou, S Vassiliou, SA Papiris, M Joo, TS Blackwell, C Roussos, D Graf, **I**

- Kalomenidis.** Tumor-derived Monocyte-Chemotactic Protein-1 promotes malignant pleural effusion. 16th Annual Congress of the Hellenic Thoracic Society. December 6-9 2007, Athens, Greece
8. Best abstract on pleural disease. I Psallidas, GT Stathopoulos, C Moschos, A Kollintza, S Karabela, P Theodoropoulou, C Roussos, **I Kalomenidis.** Inhibition of osteopontin limits malignant pleural effusion. 17th Annual Congress of the Hellenic Thoracic Society, November 20-22 2008, Alexandroupolis, Greece.
 9. Best abstract on pleural disease. I Psallidas, S Karabela, A Kollintza, P Theodoropoulou, C Roussos, **I Kalomenidis,** GT Stathopoulos. Bortezomib, a proteasome inhibitor is effective against experimental malignant pleural effusion. 17th Annual Congress of the Hellenic Thoracic Society. November 20-22 2008, Alexandroupolis, Greece
 10. Best abstract on lung cancer. I Psallidas, GT Stathopoulos, C Moschos, A Kollintza, S Karabela, P Theodoropoulou, C Roussos, **I Kalomenidis.** Inhibition of osteopontin limits malignant pleural effusion. 18th Annual Congress of the Hellenic Thoracic Society. November 26-29 2009, Thessaloniki, Greece
 11. Best abstract in pleural disease. M Vazakidou, S Magouta, S Karabela, M Stratiki, C Roussos, S Papiris, **I Kalomenidis.** Inhibition of mTOR retards malignant mesothelioma growth, 19th Annual Congress of the Hellenic Thoracic Society. October 21-24 2010, Rodhos, Greece.
 12. Best Abstract of the Congress. M Vazakidou, S Magouta, C Moschos, M Stratiki, S Papiris, **I Kalomenidis.** Inhibition of mTOR retards malignant mesothelioma growth, 20th Annual Congress of the Hellenic Thoracic Society. November 24-27 2011, Athens, Greece.
 13. Best abstract in pleural disease. I Psallidas, S Magkouta, A Pappas, C Moschos, C Roussos, **I Kalomenidis.** Osteopontin silencing limits malignant mesothelioma growth 20th Annual Congress of the Hellenic Thoracic Society. November 24-27 2011, Athens, Greece.
 14. Best publication in Pulmonology of the year 2012. Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, Papiris SA, Roussos C, **Kalomenidis I.** Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. *Oncogene* 2013;32:528-35
 15. Best abstract in pleural disease. Pappas, GA, Magkouta S, Vazakidou M-E, Psallidas I, Moschos C, **Kalomenidis I.** Effect of malignant pleural effusion on pathophysiology of malignant and resident cells of the pleural cavity. 25th Annual Congress of the Hellenic Thoracic Society. 23-26 June 2016, Athens, Greece
 16. Best abstract in pleural disease. Papas A, Magkouta S, Moschos C, Kosti C, Iliopoulou M, Psarra K, **Kalomenidis I.** Targeting MTH1 in malignant pleural mesothelioma. 26th Annual Congress of the Hellenic Thoracic Society. November 9-12 2017, Athens, Greece
 17. Best abstract in pleural disease. C Kosti, S Magkouta, F Vaitisi, A Papas, H Moschos, M Iliopoulou, **I Kalomenidis.** CSF1R targeting significantly limits lung adenocarcinoma-induced malignant pleural effusion. 27th Annual Congress of the Hellenic Thoracic Society. December 13-16 201, Athens, Greece

SCHOLARSHIPS and GRANTS

1. **I Kalomenidis.** Annual Scholarship from the Hellenic Thoracic Society for postgraduate studies. Athens 1999
2. **I Kalomenidis,** C Roussos. The role of angiopoietins-1 and -2 in the pathogenesis and progression of malignant pleural effusion. GSK annual grand for research in respiratory medicine (15,000 Euro), 2005.
3. GT Stathopoulos, **I Kalomenidis.** The role of tumor-derived Monocyte Chemoattractant Protein-1 in the pathogenesis and progression of malignant pleural effusions. Hellenic Thoracic Society annual grand for research in respiratory medicine (15,000 Euro), 2007.
4. I Psallidas, **I Kalomenidis.** The role of osteopontin in malignant pleural effusions. GSK annual grand for research in respiratory medicine (15,000 Euro), 2007.
5. **I Kalomenidis.** Conventional Chemotherapy plus zoledronic acid in malignant pleural

- mesothelioma. A preclinical study. Hellenic Thoracic Society annual grand for research in respiratory medicine (15,000 Euro), 2008.
6. **I Kalomenidis** Effects of mTOR inhibition in malignant mesothelioma growth and chemosensitivity in vivo. Hellenic Thoracic Society annual grand for research in respiratory medicine (15,000 Euro), 2009.
 7. S Magkouta, **I Kalomenidis**. Impact of angiopoietins in malignant mesothelioma growth in vivo.” Hellenic Thoracic Society annual grand for research in respiratory medicine (15,000 Euro), 2011.
 8. C Moschos, **I Kalomenidis**. Determination of the optimal technique for pleural smear preparation in order to assess cell differential counts. Hellenic Thoracic Society collaborative grant (5,000 Euro), 2013.
 9. A Pappas, **I Kalomenidis**. MTH1 inhibition halts mesothelioma growth in vivo. Hellenic Thoracic Society annual grand for research in respiratory medicine (15,000 Euro), 2015.
 10. A Pappas, **I Kalomenidis**. Role of versican in malignant pleural mesothelioma. IKY-Siemens Research Scholarship (50.000 Euro), 2016
 11. S Magkouta, **I Kalomenidis**. Role of CSF1R inhibitor in mesothelioma treatment. Hellenic Thoracic Society annual grand for research in respiratory medicine (15,000 Euro), 2017.
 12. Project Partner in the project BronchoBOC (ERA PerMed Joint Transnational Call 2019) - coordinator Maria Tsoumakidou

EDITORIAL POSITIONS:

Associate editor, *Respirology*.2012 - today

Invited Editor, *International Pleural Newsletter* for the 2008; 6(2) and 2009;7(3) issues

PEER REVIEWING

American Journal of Perinatology, American Journal of Respiratory and Critical Care Medicine, Annals of Thoracic Medicine, BMC Pulmonary Medicine, BMC Research Notes, Canadian Respiratory Journal, Case Reports in Medicine, Chest, Clinical Lung Cancer, Clinical Science, Disease Markers, European Journal of Histochemistry, European Journal of Internal Medicine, European Respiratory Journal, ERJ Open Research, Journal of Neonatal-Perinatal Medicine, Journal of Thoracic Oncology, Lung, Lung Cancer, International Journal of Tuberculosis and Lung Diseases, Respiration, Respirology, Respiratory Physiology and Neurobiology, Respiratory Medicine, Southern Medical Journal, Tohoku Journal of Experimental Medicine, Thorax, Tumori, Pneumon.

SERVICE-ELECT AT SCIENTIFIC POSITIONS

1. Coordinator, Hellenic Thoracic Society, Pleural Diseases Interest Group, 2003-2005.
2. Secretary of the Pleural and Mediastinal Malignancies Scientific subgroup of the European Respiratory Society, elected 2012

INVITED SPEAKER AT SCIENTIFIC MEETINGS:

National meetings

- 1) *Research in immunomodulation and gene therapy in lung cancer*. 14th Postgraduate Seminar of Greek Bronhology Society. April 11–12 1998. Athens, Greece.
- 2) *Interstitial lung disease associated with connective tissue diseases and vasculitides*.15th Postgraduate Seminar of Greek Bronhology Society. June 19-20 1999. Athens, Greece.
- 3) *VAP: Predisposing factors. Prevention and Management*. Annual Congress of the Hellenic Society of Intensive Care Medicine. October 7–10 1999. Athens, Greece.
- 4) *Diagnosis of Bronchiectasis*. 10th Annual Congress of Hellenic Respiratory Society. December 1 – 5 1999, Athens, Greece.
- 5) *What is new in early lung cancer diagnosis?* 16th Postgraduate Seminar of Greek Bronhology Society. May 27 - 28 2000, Athens, Greece.

- 6) *Modern diagnostic techniques in tuberculosis*. 2nd Meeting for tuberculosis. March 3 2001. Athens, Greece.
- 7) *Bilateral hilar lymphadenopathy and pleural effusion*. 17th Postgraduate Seminar of Greek Bronhology Society. June 16-17 2000. Athens, Greece.
- 8) Presenter in case presentation panel. 7th State of the art Interdisciplinary Review Course on Infections, Thoracic and Critical Care Medicine. April 17-20 2003. Athens, Greece.
- 9) *Diagnosis of pleural diseases*. Postgraduate Seminars of the Department of Critical Care and Pulmonary Services. Athens University Medical School. May 29 2003. Athens, Greece.
- 10) *Treatment of malignant pleural effusions*. 8th Interdisciplinary Postgraduate Seminar. October 31–November 1 2003. Thessaloniki, Greece.
- 11) *Pathogenesis and etiology of pleural exudates and transudates*. 12th Annual Congress of Hellenic Thoracic Society. December 3-7 2003. Athens, Greece.
- 12) *Pleural Effusions*. Postgraduate Seminars of the Department of Critical Care and Pulmonary Services. Athens University Medical School. January 15 2004. Athens, Greece.
- 13) *Clinical evaluation of patients with pleural effusions*. 12th Annual Postgraduate Seminar of the Greek Thoracic Society. February 19 2004. Athens, Greece.
- 14) *Eosinophilic pleural effusions*. Hellenic Thoracic Society Pleural Disease Working Group Meeting. February 25-26 2004. Larisa, Greece.
- 15) Presenter in exemplary reading of unknown film panel. 8th State of the art Interdisciplinary Review Course on Infections, Thoracic and Critical Care Medicine. May 7-9 2004. Athens, Greece.
- 16) *Eosinophilic pleural effusions*. 8th State of the art Interdisciplinary Review Course on Infections, Thoracic and Critical Care Medicine. May 7-9 2004. Athens, Greece.
- 17) *Pneumothorax-associated pleural eosinophilia: role of IL-5, IL-13 and TNFalpha and effects of corticosteroids*. Research meetings of the Department of Critical Care and Pulmonary Services, Athens University Medical School. April 29 2004. Athens, Greece.
- 18) *Management of spontaneous pneumothorax*. 9th Interdisciplinary Postgraduate Seminar. November 12-13 2004. Thessaloniki Greece
- 19) *Current treatment of malignant pleural mesothelioma*. 13th Annual Congress of the Hellenic Thoracic Society. December 2-5 2004. Patras, Greece
- 20) *Management of chylothorax*. 10th Interdisciplinary Postgraduate Seminar. November 11-13 2005. Athens, Greece.
- 21) *Pleural effusions in auto-immune diseases*. 14th Annual Congress of the Hellenic Thoracic Society. December 1-4 2005. Thessaloniki, Greece.
- 22) *Treatment of latent tuberculous infection*. 11th Postgraduate Seminar of “Evangelimsos” hospital. February 23-25 2006. Athens, Greece.
- 23) *Clinical Evaluation of biochemical markers in pleural effusions*. 10th State-of-the-Art Interdisciplinary Review on Pulmonary Diseases, Critical Care Medicine and Nursing Care. April 6-9 2006. Athens, Greece.
- 24) *Management of parapneumonic pleural effusions and thoracic empyema*. 32th Annual Greek Medical Congress. May 9-13 2006. Athens, Greece.
- 25) *Pleural fibrosis: mediators, complications and therapy*. 15th Annual Congress of the Hellenic Thoracic Society. November 2-5 2006. Iraklion, Greece
- 26) *Pleural Diseases. Clinical Year in Review*. 15th Annual Congress of the Hellenic Thoracic Society. November 2-5 2006, Iraklion, Greece.
- 27) *Management of patients with pleural effusion of indeterminate etiology*. 11th Interdisciplinary Postgraduate Seminar. December 8-12 2006. Thessaloniki, Greece.

- 28) *Lung biopsy study: flow limitation in COPD*. 11th State of the art Interdisciplinary Review Course on Infections, Thoracic and Critical Care Medicine. April 22-24 2007. Athens, Greece.
- 29) *Zolendronic Acid limits malignant pleural effusion in mice*. Hellenic Thoracic Society Pleural Disease Working Group Meeting. June 16-17 2007. Mt Pelion, Greece.
- 30) *Pleural effusions in cardiovascular diseases*. 12th Interdisciplinary Postgraduate Seminar. November 9-10 2007. Ioannina, Greece.
- 31) *Management of parapneumonic pleural effusions and thoracic empyema*. 12th Interdisciplinary Postgraduate Seminar. November 9-10 2007. Ioannina, Greece.
- 32) *Clinical features of patients with pleural effusions*. 16th Annual Congress of the Hellenic Thoracic Society. December 6-9 2007. Athens, Greece.
- 33) *Pleural effusions: treatment mistake*. 16th Annual Post-graduate Seminar of the Hellenic Thoracic Society. Athens, March 6 2008.
- 34) *Arterial Blood gasses analysis*. 14th Annual Congress of the Hellenic Society of Internal Medicine. Athens September 30- October 3 2008
- 35) *Management of malignant pleural mesothelioma*. 12th Interdisciplinary Postgraduate Seminar. Athens October 24-25 2008.
- 36) *Pleural effusions due to cardiovascular diseases*. 17th Annual Congress of the Hellenic Thoracic Society. November 20-22 2008, Alexandroupolis, Greece.
- 37) *Letter to the editor. Editorials. In the seminar: "How to write a medical article?"* 17th Annual Congress of the Hellenic Thoracic Society. November 20-22 2008, Alexandroupolis, Greece.
- 38) *Management of malignant pleural mesothelioma*. Respiratory Medicine Course of the Respiratory Department of the University of Thessaly. September 18-19 2009, Larissa, Greece.
- 39) *Mesothelioma: update on diagnosis and treatment*. 18th Annual Congress of the Hellenic Thoracic Society. November 26-29 2009, Thessaloniki, Greece.
- 40) *Management of a patient with pleural effusion*. 18th Annual Postgraduate Course of the Hellenic Thoracic Society. March 1 2010, Athens, Greece.
- 41) *Mesothelioma*. Lung Cancer. June 10-13 2010, Corfu, Greece.
- 42) *Treatment of malignant pleural effusions: limitations and prospects*. 14th State of the Art Course. June 17-19 2010, Athens, Greece.
- 43) *Novel pro-permeability properties of osteopontin contribute to the formation of malignant pleural effusion*. 15th State of the Art Course. April 7-9 2011, Athens Greece
- 44) *Eosinophilic Pleural Effusions*. 11th Postgraduate Seminar of the Respiratory Department of the University of Ioannina. May 26-29 2011, Ioannina, Greece
- 45) *TB pleural effusion: diagnostic approach*. Respiratory Medicine Course of the Respiratory Department of the University of Thessaly. September 9-11 2011, Pelion, Greece
- 46) *Malignant Pleural Effusion: ten critical questions*. 20th Annual Congress of the Hellenic Thoracic Society. November 24-27 2011, Athens, Greece.
- 47) *Management of patients with allergic rhinitis and asthma according to international guidelines (ARIA, GINA)*. 16th National Conference of the Hellenic ENT Society. Athens December 1-4/2012.
- 48) *Thoracic Ultrasound in Clinical Practice: 3rd Thoracic Ultrasound Seminar*. September 9 2012, Larisa, Greece.
- 49) *ADA 2012*. 21st Annual Congress of the Hellenic Thoracic Society. October 18-21 2011, Athens, Greece.
- 50) *Pro-con debate. Fibrinolytics in pleural empyema* 21st Annual Congress of the Hellenic Thoracic Society. October 18-21 2012, Athens, Greece.
- 51) *Treatment of malignant pleural effusions*. 12th Conference of the Department of Pulmonology, University of Ioannina, School of Medicine. April 26-29 2013, Corfu, Greece.
- 52) *Management of malignant pleural effusions beyond pleurodesis*. 22nd Annual Congress of the Hellenic Thoracic Society. December 5-8 2013, Athens, Greece.
- 53) *Ultrasound-guided thoracentesis*. 7th Conference on Oncology in Primary Care and Technology. December 13-14 2013, Athens, Greece.
- 54) *Management of parapneumonic pleural effusion*. 21st postgraduate symposium of the Hellenic Thoracic Society – Southwest Greece Committee. May 30 - June 1 2014, Kalamata, Greece.
- 55) *Arterial blood gases – from theory to clinical practice*. 20th Hellenic Congress of Internal Medicine.

- December 11-13 2014, Athens, Greece.
- 56) *Management of empyema of the thoracic cavity*. 20th Annual Seminar of Medical Education of Evangelismos Hospital. February 16-20 2015, Athens Greece.
 - 57) *Diagnostic Approach of patients with a Pleural Effusion*. Seminar on Thoracic Drainage and Thoracic Ultrasound. Thessaloniki, April 3-4 2015.
 - 58) *Pleural fluid evaluation*. 19th Seminar of the Hellenic Society of Clinical Chemistry and Clinical Biochemistry “Biochemical tests in Biological Fluids”. Athens May 9 2015.
 - 59) *Chest imaging in systemic diseases*. 41st Annual Hellenic Medical Congress. Athens 10-13 June 2015.
 - 60) *Surgical treatment of mesothelioma*. 24th Annual Congress of the Hellenic Thoracic Society. November 26-29 2015, Athens, Greece.
 - 61) *Thoracic ultrasound: from theory to clinical practice*. 25th Annual Congress of the Hellenic Thoracic Society. June 22-26 2016, Athens, Greece.
 - 62) *Endoscopies of the respiratory system*. 9th National Conference of the Hellenic Society of Infection Control. November 2-4 2016, Athens, Greece.
 - 63) *Importance of ADA in the evaluation of pleural effusions*. Pulmonology Days. April 21-24 2017, Volos, Greece.
 - 64) *Acute respiratory failure in patients with diffuse parenchymal disease*. 1st Symposium of the 1st Department of Critical Care and Pulmonary Medicine of the University of Athens School of Medicine. May 26-27 2017, Athens, Greece
 - 65) *Tuberculous pleural effusion*. 26th Annual Congress of the Hellenic Thoracic Society. November 9-12 2016, Athens, Greece.
 - 66) *Diagnostic plan for patients with pleural effusions*. 3d Congress of Thoracic and environmental diseases. May 10-13 2018, Thessaloniki, Greece
 - 67) *Pleural effusion at the outpatient clinic*. 3rd Symposium of the 1st Department of Critical Care and Pulmonary Medicine of the University of Athens School of Medicine. May 18-19 2018, Athens, Greece
 - 68) *Chest ultrasound in ICU*. Intensive Care and Emergency Medicine Seminar. October 5-7 2018, Plastiras Lake, Greece.
 - 69) *Diagnostic Approach of patients with pleural effusions*. Achaean Medical Days. April 13-14/2019, Patras, Greece.
 - 70) *Pleural diseases*. 5th Symposium of the 1st Department of the Department of Critical Care, University of Athens, School of Medicine. May 10-11/2019, Athens, Greece.
 - 71) *Lung Ultrasound. Υπερηχογράφημα πνεύμονα*. 1st Clinical Meeting in Basic Ultrasound in ICU. Athens, November 2-3 2019
 - 72) *Technical aspects of thoracic ultrasound – normal images*. 28th Annual Congress of the Hellenic Thoracic Society. Athens, December 12-15/2019
 - 73) *ADA is useful in the diagnosis of TB pleuritic. Against*. 28th Annual Congress of the Hellenic Thoracic Society. Athens, December 12-15/2019








International Meetings

- 1) *Novel management approach for malignant pleural effusions: targeting pleural fluid formation*. 9th International Conference of the International Mesothelioma Interest Group. May 25-27 2008, Amsterdam, Holland.
- 2) *Management of patients with malignant pleural disease: overview*. Approach to pleural cancer: state-of-the-art. European School of Oncology. May 7-8 2009, Athens, Greece.
- 3) *Diagnosis and treatment of malignant pleural effusion*. 3d Congress of the Bulgarian Respiratory Society. June 3-6 2010, Plovdiv, Bulgaria.
- 4) *A frequent diagnostic dilemma: TB or not TB*. 42nd Union Conference on Lung Health (International Union Against Tuberculosis and Lung Disease). October 26-30 2011, Lille, France.
- 5) *Pneumothorax and mediastinum*. 1st HTS-ERS HERMES Summer School. July 5-8 2012, Heraklion, Greece.
- 6) *Workshop Pleural and Mediastinal Diseases*. 1st HTS-ERS HERMES Summer School. July 5-8 2012, Heraklion, Greece.

- 7) *Understanding pathophysiology of malignant pleural effusion: Potential new therapies.* American Thoracic Society International Conference. May 17-22 2013, Philadelphia, USA.
- 8) *Pneumothorax and mediastinum.* 2nd HTS-ERS HERMES Summer School. June 30- July 2 2013, Heraklion, Greece.
- 9) *Workshop Pleural and Mediastinal Diseases.* 2nd HTS-ERS HERMES Summer School. June 30- July 2 2013, Heraklion, Greece.
- 10) *Pneumothorax and mediastinum.* 3d HTS-ERS HERMES Summer School. Athens, Greece 28-31/8/2014.
- 11) *Workshop Pleural and Mediastinal Diseases.* 2nd HTS-ERS HERMES Summer School. 3d HTS-ERS HERMES Summer School. Athens, Greece 28-31/8/2014.
- 12) *Interventional US in the thorax.* Euroson School. Elastography and Interventional US. February 15-16 2014, Athens, Greece.
- 13) *Diagnostic Approach of Mesothelioma.* Advanced Course in Pathology of Ovarian Tumors and Mesothelioma. April 28-29 2015, Athens, Greece.
- 14) *Diagnostic Approach for Patients with a Pleural Effusion. Respiratory Diseases in General Practice. The specialist's perspective.* June 6-7 2015, Limassol, Cyprus.
- 15) *Pneumothorax and mediastinum.* 4th HTS-ERS HERMES Summer School. 3-6/9/2015 Athens, Greece.
- 16) *Workshop Pleural and Mediastinal Diseases.* 4th HTS-ERS HERMES Summer School. 3-6/9/2015 Athens, Greece.
- 17) *Role of Ultrasound in Pleural Diseases.* 27th Congress of EFUSMB-EUROSON 2015. 6-8/11/2015. Athens, Greece.
- 18) *Pneumothorax and mediastinum.* 5th Hellenic Summer School. 25-28/8/2016 Athens, Greece.
- 19) *Workshop Pleural and Mediastinal Diseases.* 5th Hellenic Summer School. 25-28/8/2016 Athens, Greece.
- 20) *Basic research studies in malignant pleural effusion.* ERS International Congress 2016. 3-7/9/2016 London, UK.
- 21) *Diagnostic Approach of Patients With Pleural Effusions.* 2019 CHEST Regional Congress, Athens, June 27-29 2019

PUBLICATIONS

A. ORIGINAL ARTICLES (Indexed in Pubmed/ISI Web of science)

-  Toumbis M, Rasidakis A, Passalidou E, **Kalomenidis J**, Alchanatis M, Orphanidou D and Jordanoglou J. Evaluation of Cyfra 21-1 in malignant and benign pleural effusions. *Anticancer Research* 1996; 16: 2101 – 2104.
-  Orphanidou D, **Kalomenidis J**, Rasidakis A, Papamichalis G, Toumbis M, Labaditis J, Sacharidou A, Papastamatiou H and Jordanoglou J. Immunohistochemical detection of p53 protein in neoplastic, preneoplastic and normal bronchial mucosa specimens obtained during diagnostic bronchoscopy. *Oncology Reports* 1998; 5:763 – 769.
-  Rasidakis A, Orphanidou D, **Kalomenidis J**, Papamichalis G, Toumbis M, Labaditis J, Sacharidou A, Papastamatiou H, Jordanoglou J. Expression of mdm-2 protein in neoplastic, preneoplastic and normal bronchial mucosa: comparative study with p53 expression. *Hybridoma* 1998; 17: 339 – 345.
-  **Kalomenidis I**, Orphanidou D, Papamichalis G, Vassilakopoulos T, Skorilas A, Rasidakis A, Papastamatiou H, Jordanoglou J, Roussos C. Combined expression of p53, Bcl-2 and p21^{WAF-1} proteins in lung cancer and premalignant lesions: association with clinical characteristics. *Lung* 2002; 179:265-78.
-  **Kalomenidis I**, H Mohamed KH, Lane KB, Peebles RS, Barnette R, Rodriguez RM, Light RW. Pleural fluid levels of vascular cell adhesion molecule-1 are elevated in eosinophilic pleural effusions. *Chest* 2003; 124: 159-66.
-  **Kalomenidis I**, Rodriguez RM, Barnette R, Gupta R, Hawthorne M, Parkes KB, Light RW. Patient with bilateral pleural effusion: are the findings the same in each fluid? *Chest* 2003; 124:167-76.
-  **Kalomenidis I**, Dimakou K, Kolintza N, Vlami K, Papadakis M, Sotiropoulou C, Roussos C, Papiris S. Sputum CEA, NSE and CYFRA 21-1 levels in lung cancer diagnosis. *Respirology* 2004; 9: 54-9.

- 📁📄👤 **Kalomenidis I**, Guo Y, Lane KB, Hawthorne M, Light RW. TGF- β 3 induces pleurodesis in rabbits and collagen production of human mesothelial cells. *Chest* 2005; 127:1335-40.
- 📁📄👤 **Kalomenidis I**, Stathopoulos GT, Barnette R, Guo, Peebles RS, Blackwell TS, Light RW. Eotaxin-3 and interleukin-5 pleural fluid levels are associated with pleural fluid eosinophilia in post-coronary artery by-pass grafting pleural effusions. *Chest* 2005; 127:2094-2100.
- 📁📄👤 Guo Y, **Kalomenidis I**, Hawthorne M, Parman KS, Lane KB, Light RW. Pleurodesis Is Inhibited By Anti-Vascular Endothelial Growth Factor Antibody. *Chest* 2005; 128:1790-7.
- 📁📄👤 **Kalomenidis I**, Guo Y, Peebles RS, Lane KB, Papiris S, Elias J, Light RW. Pneumothorax-associated pleural eosinophilia in mice is Interleukin-5 but not Interleukin-13-dependent. *Chest* 2005; 128:2978-83.
- 📁📄👤 Stathopoulos GT, Zhu Z, Everhart MB, **Kalomenidis I**, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, Blackwell TS. Nuclear Factor- κ B Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion. *Am J Respir Cell Mol Biol* 2006; 34:142-150.
- 📁📄👤 **Kalomenidis I**, Kollintza A, Sigala I, Papapetropoulos A, Papiris S, Light RW, Roussos C. Pleural fluid Angiopoietin-2 levels are elevated in exudative pleural effusions. *Chest* 2006; 129:1259-66
- 📁📄👤 **Kalomenidis I**, Stathopoulos GT, Barnette R, Papiris S, Blackwell TS, Roussos C, Light RW. Vascular endothelial growth factor levels in post-CABG pleural effusions are associated with pleural inflammation and permeability. *Resp Medicine* 2007; 101: 223–229.
- 📁📄👤 Papiris SA, **Kalomenidis I**, Malagari K, Kapotsis GE, Harhalakis N, Manali ED, Rontogianni D, Roussos C, Moutsopoulos HM. Extranodal marginal zone B-cell lymphoma of the lung in Sjogren's syndrome patients. Reappraisal of clinical, radiological, and pathology findings. *Resp Medicine* 2007; 101, 84–92.
- 📁📄👤 Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, **Kalomenidis I**. Tumor Necrosis Factor- α Promotes Malignant Pleural Effusion. *Cancer Res.* 2007; 67:9825-34.
- 📁📄👤 Manali ED, Stathopoulos GT, Kollintza A, **Kalomenidis I**, Emili JM, Sotiropoulou C, Daniil Z, Roussos C, Papiris SA. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. *Respir Med.* 2008; 102: 586-92.
- 📁📄👤 **Kalomenidis I**, Moschos C, Kollintza A, Sigala I, Stathopoulos GT, Papiris SA, Light RW, Roussos C. Pneumothorax-associated pleural eosinophilia is TNF- α -dependent and attenuated by steroids. *Respirology* 2008; 13: 73-78.
- 📁📄👤 Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Zhou Z, Papiris SA, Roussos C, **Kalomenidis I**. Zoledronic Acid is Effective Against Experimental Malignant Pleural Effusion. *Am J Respir Crit Care Med.* 2008; 178:50-59.
- 📁📄👤 Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, **Kalomenidis I**. A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion. *J Natl Cancer Inst.* 2008; 100: 1464-76.
- 📁📄👤 Moschos C, Psallidas I, Kollintza A, Karabela S, Papapetropoulos A, Papiris S, Light RW, Roussos C, Stathopoulos GT, **Kalomenidis I**. The angiopoietin/tie2 axis mediates malignant pleural effusion formation. *Neoplasia* 2009; 11: 298-304.
- 📁📄👤 Moschos C, Porfyridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, **Kalomenidis I**. Osteopontin is upregulated in malignant and inflammatory pleural effusions. *Respirology* 2009; 14: 716-22.
- 📁📄👤 Guo Y, Tang K, Bilaceroglu S, **Kalomenidis I**, Salleng KJ, Lane KB, Light RW. Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits. *Respirology* 2010; 15: 119-25.
- 📁📄👤 Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, **Kalomenidis I**, Stathopoulos GT. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. *Mol Cancer* 2010; 9:56.
- 📁📄👤 Doris K, Karabela SP, Kairi CA, Simoes DC, Roussos C, Zakynthinos SG, **Kalomenidis I**, Blackwell TS, Stathopoulos GT. Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs mice. *Respir Res.* 2010; 11: 118.
- 📁📄👤 Zarogiannis S, Psallidas I, Hatzoglou C, Gourgoulis KI, **Kalomenidis I**. Dexamethasone acutely accelerates pleural fluid absorption in mice hydrothoraces. *J Physiol Sci.* 2010; 60: 299-302.
- 📁📄👤 Oikonomidi S, Kostikas K, **Kalomenidis I**, Tsilioni I, Daenas Ch, Gourgoulis KI, Kiropoulos TS. Matrix metalloproteinases levels in the differentiation of parapneumonic pleural effusions. *Respiration* 2010; 80:285-91.

- Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, **Kalomenidis I**, Roussos C, Fingleton B, Yull FE, Peebles Jr RS, Blackwell TS. Host-derived Intreleukin-5 Promotes Adenocarcinoma-induced Malignant Pleural Effusion. *Am J Respir Crit Care Med*. 2010; 182:1273-81.
- Tsilioni I, Kostikas K, **Kalomenidis I**, Oikonomidi S, Tsolaki V, Minas M, Gourgoulisanis KI, Kiroopoulos TS. Diagnostic accuracy of biomarkers of oxidative stress in parapneumonic pleural effusion. *Eur J Clin Invest*. 2011; 41:349-56.
- Moschos C, Psallidas I, Cottin T, Kollintza A, Papiris S, Roussos C, Stathopoulos GT, Giannis A, Kalomenidis I. A sulindac analogue is effective against malignant pleural effusion in mice. *Lung Cancer* 2011; 73:171-5.
- Karabela SP, Kairi CA, Magkouta S, Psallidas I, Moschos C, Stathopoulos I, Zakyntinos SG, Roussos C, **Kalomenidis I**, Stathopoulos GT. Neutralization of Tumor Necrosis Factor bioactivity ameliorates Urethane-induced pulmonary oncogenesis in mice. *Neoplasia* 2011; 13:1143-5.
- Skouras V, Bouladakis E, Nikoulis D, Polychronopoulos V, Daniil Z, **Kalomenidis I**, Gourgoulisanis K. Prognostic value of C-reactive protein in parapneumonic effusions. *Respirology* 2012; 17:308-14.
- Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, Vassiliou S, McMahon F, Gleaves LA, Han W, Stathopoulos I, Zakyntinos SG, Yull FE, Roussos C, **Kalomenidis I**, Blackwell TS, Stathopoulos GT. Opposing effects of bortezomib-induced nuclear factor- κ B inhibition on chemical lung carcinogenesis. *Carcinogenesis*. 2012; 33: 859-67.
- Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, Papiris SA, Roussos C, **Kalomenidis I**. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. *Oncogene* 2013; 32: 528-35.
- Kollintza A, Magkouta S, Psallidas I, Moschos C, Stratiki M, Esquerda A, Porcel JM, **Kalomenidis I**. Interleukin-17A is involved in bacteria-related acute pleural inflammation. *Respirology* 2013; 18: 488-94.
- Rovina N, Psallidas I, Moschos C, Kollintza A, **Kalomenidis I**. Interleukin-18 is up-regulated in infectious pleural effusion. *Cytokine* 2013; 63: 166-71.
- Marazioti A, Kairi CA, SPella M, Giannou AD, Magkouta S, Giopanou I, Papaleonidopoulos V, **Kalomenidis I**, Snyder LA, Kardamakis D, Stathopoulos GT. Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion. *PLoS One* 2013; 8: e71207.
- VK Kouritas, S Magkouta, C Zisis, I Psalidas, KI Gourgoulisanis, **I Kalomenidis**. Paracetamol and Ibuprofen block hydrothorax absorption in mice. *Eur J Cardiothorac Surg*. 2015; 47:426-30.
- Skouras VS, Magkouta SF, Psallidas I, Tsilioni I, Maragozidis P, Gourgoulisanis KI, Kalomenidis I. Interleukin-27 improves the ability of adenosine deaminase to rule-out tuberculous pleural effusion regardless of pleural tuberculosis prevalence. *Infectious Disease* 2015; 47:477-83.
- Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, Papaleonidopoulos V, Kairi CA, Patmanidi AL, Giopanou I, Spiropoulou N, Harokopos V, Aidinis V, Spyrtos D, Teliousi S, Papadaki H, Taraviras S, Snyder LA, Eickelberg O, Kardamakis D, Iwakura Y, Feyerabend TB, Rodewald HR, **Kalomenidis I**, Blackwell TS, Agalioiti T, Stathopoulos GT. Mast cells mediate malignant pleural effusion formation. *J Clin Invest* 2015; 125: 2317-34.
- Vazakidou ME, Magkouta S, Moschos C, Psallidas I, Pappas A, Psarra K, **Kalomenidis I**. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo. *Respirology* 2015; 20:1263-71.
- Magkouta S, Pappas A, Moschos C, Vazakidou ME, Psarra K, **Kalomenidis I**. Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion. *Oncotarget*. 2016; 7: 20249 – 20259.
- Anastasakos V, Skouras V, Moschos C, Tsikrika S, Karabela S, Marinou I, Vogiatzakis E, Konstantinou K, Papavasiliou A, **Kalomenidis I**. Patterns of drug resistance among patients with tuberculous pleural effusion in Greece. *Int J Tuberc Lung Dis*. 2017;21:309-313
- Pett SL, Kunisaki KM, Wentworth D, Griffin TJ, **Kalomenidis I**, Nahra R, Montejano Sanchez R, Hodgson SW, Ruxrungtham K, Dwyer D, Davey RT, Wendt CH; INSIGHT FLU003 Plus Study Group. Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. *Open Forum Infect Dis*. 2017; 5:ofx228.
- Wentworth D, Uyeki TM, Gordin F, Angus B, Qvist T, Emery S, Lundgren J, Neaton JD; INSIGHT Influenza Study Group (**Kalomenidis I**, member of the group). Comparison of the Outcomes of

Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Open Forum Infect Dis. 2017;4:ofx212.

- Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications. Magkouta S, Pappas A, Pateras IS, Kollintza A, Moschos C, Vazakidou ME, Karavana V, Gorgoulis VG, *Kalomenidis I*. *Oncotarget*. 2018;9:21783-21796
- Glynos C, Bibli SI, Katsaounou P, Pavlidou A, Magkou C, Karavana V, Topouzis S, *Kalomenidis I*, Zakyntinos SG, Papapetropoulos A. Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice. *Am J Physiol Lung Cell Mol Physiol*. 2018; 315:L662-L672
- Role of angiopoietins in mesothelioma progression Magkouta S, Kollintza A, Moschos C, Spella M, Skianis I, Pappas A, Vazakidou ME, Stathopoulos G, *Kalomenidis I*. *Cytokine* 2018; pii: S1043-4666(18)30341-7.
- Pappas AG, Magkouta S, Pateras IS, Skianis I, Moschos C, Vazakidou ME, Psarra K, Gorgoulis VG, *Kalomenidis I*. Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth. *Oncoimmunology*. 2018;8:e1537427
- Kerdidani D, Chouvardas P, Arjo AR, Giopanou I, Ntaliarda G, Guo YA, Tsikitis M, Kazamias G, Potaris K, Stathopoulos GT, Zakyntinos S, *Kalomenidis I*, Soumelis V, Kollias G, Tsoumakidou M. Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. *Nat Commun*. 2019;10:1405.
- Giopanou I, Kanellakis NI, Giannou AD, Lilis I, Marazioti A, Spella M, Papaleonidopoulos V, Simoes DCM, Zazara DE, Agalioti T, Moschos C, Magkouta S, *Kalomenidis I*, Panoutsakopoulou V, Lamort AS, Stathopoulos GT, Psallidas I. Osteopontin drives KRAS-mutant lung adenocarcinoma. *Carcinogenesis*. 2020 in press
- Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD;INSIGHT FLU-IVIG Study Group. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomized, placebo-controlled trial. *Lancet Respir Med*. 2019;7:951-963.
- Kerdidani D, Chouvardas P, Arjo AR, Giopanou I, Ntaliarda G, Guo YA, Tsikitis M, Kazamias G, Potaris K, Stathopoulos GT, Zakyntinos S, Kalomenidis I, Soumelis V, Kollias G, Tsoumakidou M. Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. *Nat Commun*. 2019 Mar 29;10(1):1405. doi: 10.1038/s41467-019-09370-z PMID: 30926812
- Papalampidou A, Bibaki E, Boutlas S, Pantazopoulos I, Athanasiou N, Moylan M, Vlachakos V, Grigoropoulos V, Eleftheriou K, Daniil Z, Gourgoulis K, Kalomenidis I, Zakyntinos S, Ischaki E. Nasal high-flow oxygen versus noninvasive ventilation in acute exacerbation of COPD: protocol for a randomised noninferiority clinical trial. *ERJ Open Res*. 2020 Oct 19;6(4):00114-2020. doi: 10.1183/23120541.00114-2020. eCollection 2020 Oct. PMID: 33123554
- Magkouta SF, Pappas AG, Vaitsi PC, Agioutantis PC, Pateras IS, Moschos CA, Iliopoulou MP, Kosti CN, Loutrari HV, Gorgoulis VG, Kalomenidis IT. MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage. *JCI Insight*. 2020 Jun 18;5(12):e134885. doi: 10.1172/jci.insight.134885
- Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB,

- Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440
- 📄📄📄 Tsolaki V, Zarogiannis S, Zygoulis P, Kalomenidis I, Jagirdar R, Makris D, Daniil Z, Magkouta S, Triantafyllou I, Papanikolaou J, Gourgoulis KI, Zakynthinos E. Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications. *Respirology*. 2020 Oct;25(10):1060-1065. doi: 10.1111/resp.13788.
- 📄📄📄 Sigala I, Alevizopoulos N, Elefteriou K, Gianniou N, Kalomenidis I. Primary squamous cell carcinoma of the pleura treated with nivolumab. *Respirol Case Rep*. 2020 Feb 5;8(2):e00516. doi: 10.1002/rcr2.516. eCollection 2020 Mar. PMID: 32042427
- 📄📄📄 Giopanou I, Kanellakis NI, Giannou AD, Lilis I, Marazioti A, Spella M, Papaleonidopoulos V, Simoes DCM, Zazara DE, Agalioti T, Moschos C, Magkouta S, Kalomenidis I, Panoutsakopoulou V, Lamort AS, Stathopoulos GT, Psallidas I. Osteopontin drives KRAS-mutant lung adenocarcinoma. *Carcinogenesis*. 2020 Aug 12;41(8):1134-1144. doi: 10.1093/carcin/bgz190. PMID: 31740923
- 📄📄📄 Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD; INSIGHT FLU-IVIG Study Group. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. *Lancet Respir Med*. 2019 Nov;7(11):951-963. doi: 10.1016/S2213-2600(19)30253-X. PMID: 31582358
- 📄📄📄 Peppas VG, Solenov EI, Kalomenidis I, Tsilioni I, Gourgoulis KI, Hatzoglou C, Zarogiannis SG. *Respir Physiol Neurobiol*. 2021 Mar;285:103581. doi: 10.1016/j.resp.2020.103581. Epub 2020 Nov 12. Pleural effusion osmolality correlation with pH and glucose level of pleural fluid and its effects on the pleural membrane permeability.
- 📄📄📄 Routsis C, Magira E, Kokkoris S, Siembos I, Vrettou C, Zervakis D, Ischaki E, Malahias S, Sigala I, Asimakos A, Daidou T, Kaltsas P, Douka E, Sotiriou A, Markaki V, Temberikidis P, Koroneos A, Politis P, Mastora Z, Dima E, Tsoutsouras T, Papahatzakis I, Gioni P, Strilakou A, Maragouti A, Mizi E, Kanavou A, Sarri A, Gavrielatou E, Mentzelopoulos S, Kalomenidis I, Papastamopoulos V, Kotanidou A, Zakynthinos S. Hospital Resources May Be an Important Aspect of Mortality Rate among Critically Ill Patients with COVID-19: The Paradigm of Greece. *J Clin Med*. 2020 Nov 20;9(11):3730. doi: 10.3390/jcm9113730.

A'. ORIGINAL ARTICLES (Not Indexed in Pubmed/ISI Web of science)

no

B. CASE REPORTS/STUDIES (Indexed in Pubmed)

1. **Kalomenidis I**, Malagari K, Margariti G, Lignos M, Psaroudaki Z, Roussos C, Papiris S. A cavitary pulmonary lesion in a 28-year-old man. Roentgenogram of the month. *Respiration* 2003; 70: 317-19.
2. Kapotsis GE, Daniil Z, Malagari K, Vamvouka C, **Kalomenidis I**, Roussos C, Papiris SA. A young male with chest pain, cough and fever. *Eur Respir J* 2004, 24:506-509.
3. Sigala I, **Kalomenidis I**, Malagari K, Rontogianni D, Kapotsis G, Vassilakopoulos T, Roussos C, Papiris SA. Dry cough and dyspnea, rapidly increasing to respiratory failure in a male smoker. *Eur Respir J* 2005, 25: 1122-25.

4. Stratakos G, *Kalomenidis I*, Pappas V, Malagari K, Kollintza A, Roussos C, Anagnostopoulou M, Paniara O, Zakyntinos S, Papiris SA. Cough and fever in a female with Crohn's disease receiving infliximab. *Eur Respir J* 2005; 26: 354-357.
5. Zisis C, Kefaloyannis EM, Rontogianni D, Michalopoulou F, *Kalomenidis I*, Papiris SA, Bellenis I. Asymptomatic chest wall Hodgkin disease mimicking fibrosing mediastinitis. *J Thorac Cardiovasc Surg.* 2006; 131:e1-2.
6. Moschos C, *Kalomenidis I*, Roussos C, Stathopoulos GT. A 35-year-old male with chronic cough. *Eur Respir J* 2007; 29:608-11.
7. Kolilekas L, Manali E, *Kalomenidis I*, Mouchtouri E, Spyrou K, Papiris S. Tracheal compression in Marfan syndrome. *Intern Med.* 2008; 47:1069-70.
8. Kolilekas L, *Kalomenidis I*, Manali E, Liberopoulos P, Papiris S. Recurrent Hemoptysis in a Patient with Previous Tuberculosis. *Respiration.* 2009; 78: 453-4.
9. Kolilekas L, Triantafyllidou C, Vrettos I, Gkikas V, *Kalomenidis I*, Manali E, Nakopoulou L, Papiris S. Diffuse alveolar infiltrates and macroscopic hematuria: a run-and-gun affair. *Respiration* 2010; 79: 511-5.
10. Sigala I, Alevizopoulos N, Eleftheriou K, Gianniou N, *Kalomenidis I*. Primary squamous cell carcinoma of the pleura treated with nivolumab. *Respirol Case Rep* 2020; 8: e00516.

B'. CASE REPORTS/STUDIES (Not indexed in Pubmed)

no

C. REVIEW ARTICLES – EDITORIALS (Indexed in Pubmed)

1. *Kalomenidis I*, Light RW. Eosinophilic Pleural Effusions. *Current Opinion in Pulmonary Medicine* 2003; 9: 254-260.
2. *Kalomenidis I*, Light RW. Pathogenesis of the eosinophilic pleural effusions. *Current Opinion in Pulmonary Medicine* 2004, 10:289–293.
3. *Kalomenidis I*, Bouros D. Pleural Fluid pH in parapneumonic pleural effusions: drawing the line. Editorial. *Respiration* 2005; 72:345–346.
4. *Kalomenidis I*. Octreotide and chylothorax. *Curr Opin Pulm Med* 2006; 12:264–267.
5. Mutsaers SE, *Kalomenidis I*, Wilson NA Lee YCG. Growth factors in pleural fibrosis. *Curr Opin Pulm Med* 2006; 12:251–258.
6. Papiris SA, Manali DE, *Kalomenidis I*, Kapotsis GE, Karakatsani A, Roussos C. Bench-to-bedside review: Pulmonary–renal syndromes - an update for the intensivist. *Critical Care* 2007; 11:213.
7. Stathopoulos GT, *Kalomenidis I*. Animal models of malignant pleural effusion. *Curr. Opin Pulm Med* 2009; 15: 343-352.
8. Skouras V, *Kalomenidis I*. Chylothorax: diagnostic approach. *Curr Opin Pulm Med.* 2010; 16:387-93.
9. *Kalomenidis I*. Beyond talc pleurodesis: do we really need new methods? *Respirology* 2011; 16: 1020-22.
10. Stathopoulos GT, *Kalomenidis I*. Malignant pleural effusion: tumor-host interactions unleashed. *Am J Respir Crit Care Med* 2012; 186:487-92.
11. Zarogiannis SG, *Kalomenidis I*. Can pharmacological agents speed the rate of resorption of pleural fluid? *Current Opin Pulm Med* *Current Opin Pulm Med* 2015; 21:372-5.
12. Skouras VS, *Kalomenidis I*. Pleural fluid tests to diagnose tuberculous pleuritic. *Curr Opin Pulm Med* 2016; 22:367–377.
13. Psallidas I, *Kalomenidis I*, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. *Eur Respir Rev* 2016; 25: 108–109.
14. Skouras V, *Kalomenidis I*. Drug resistance in patients with tuberculous pleural effusions. *Curr Opin Pulm Med* 2018; 24:374-9

C'. REVIEW ARTICLES (Not indexed in Pubmed)

1. *I Kalomenidis*, RW Light. How to approach a patient with an eosinophilic pleural effusion. *J Respir Dis* 2003; 24: 247-253.

2. ***I Kalomenidis***. Eosinophilic Pleural Effusions: a clinical approach. Intern Pleural Newsletter 2004; 2(2): 8. epub: www.musc.edu/pleuralnews.
3. ***I Kalomenidis***, RW Light, YCG Lee. Transforming Growth Factor-beta: A potential new agent for pleurodesis. Drug Design Review-Online 2005; 2: 47-51.
4. ***I Kalomenidis***. Highlighted Pleural Research Papers from 2007. Clinical Research for Pleural Diseases, 2007. International Pleural Newsletter 2008; 6 (1): 5. epub: www.musc.edu/pleuralnews.
5. C Moschos, ***I Kalomenidis***. Drug-related pleural disease. Pleural Bulletin, Turk Toraks Denergi 2010; 4: 9-18
6. Skouras VS, ***Kalomenidis I***. Pleurotoxic Drugs – an Update. Someone else to blame? Curr Pulm Reports 2019.

D. LETTERS TO THE EDITOR (Indexed in Pubmed)

1. Stratakos G, ***Kalomenidis J***, Routsis C, Papiris S, Roussos C. Transient lactic acidosis as a side effect of inhaled salbutamol. Chest 2002; 122:385-6.
2. ***Kalomenidis I***, Lane K, Guo Y, Blackwell TS, Light RW. Mice are resistant to the induction of a pleurodesis. Chest 2003; 124:2407-08.
3. ***Kalomenidis I***, Papiris S, Loukides S. Bilateral pleural effusions associated with pravastatin sodium treatment. Eur Respir J 2007; 30:1022.
4. Kolilekas L, ***Kalomenidis I***, Manali E, Triantafillidou C, Brountzos E, Papiris S. Cyanoacrylate-related pulmonary embolism following percutaneous varicocele embolization. South Med J. 2008; 101:1073-4.
5. Porfyridis I, ***Kalomenidis I***, Psallidas I, Stratakos G, Roussos C, Vassilakopoulos T, Stathopoulos GT. Etanercept-induced pleuropericardial lupus-like syndrome. Eur Respir J. 2009; 33: 939-41.
6. Vazakidou ME, Magkouta S, Moschos C, ***Kalomenidis I***. mTOR inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion. Respirology 2014; 19:290-92.
7. Iliopoulou M, Spyrtos D, Kotsiou O, Skouras V, ***Kalomenidis I***. A six-year microbiologic study of hospital-acquired and health-care associated parapneumonic pleural infection. Eur J Intern Med. 2019; 63:e12-e13.

E. CHAPTERS IN INTERNATIONAL BOOKS

1. ***I Kalomenidis***. Effusions due to drugs. In: Textbook of Pleural diseases. RW Light, YCG Lee (Edts). Arnold, 2003. pp: 382-393.
2. ***I Kalomenidis*** and YCG Lee. Chylothorax, Pseudochylothorax, LAM and Yellow Nail Syndrome. In: Encyclopedia of Respiratory Medicine Geoffrey J. Laurent and Steven D. Shapiro (Edts). Elsevier Ltd. 2006, pp: 388.
3. ***I Kalomenidis***. Effusions caused by drugs. In: Textbook of Pleural diseases. 2nd edition. RW Light, YCG Lee (Edts). Hodder Arnold, 2008. pp: 431-443.
4. R Thomas, ***I Kalomenidis***, J Jett, YCG Lee. Effusions form malignant causes. In: Textbook of Pleural diseases. 3d edition. RW Light, YCG Lee (Edts). Taylor & Francis Group, LLC, 2016. pp: 295-330
5. V Skouras, ***I Kalomenidis***. Effusions caused by drugs. In: Textbook of Pleural diseases. 3d edition. RW Light, YCG Lee (Edts). Taylor & Francis Group, LLC, 2016. pp: 397-406.

Z. CONFERENCE PROCEEDINGS

1. Papiris SA, ***Kalomenidis I***, Manali ED, Karakatsani A. Pulmonary-renal autoimmune inflammatory syndromes. ACAAI-HSACI Joint Allergy Symposium Summary Book, pp: 62-75. Athens, 6-9/9/2006.
2. ***Kalomenidis I***. Novel management approach for malignant pleural effusions: targeting pleural fluid formation. 9th International Conference of the International Mesothelioma Interest Group. Amsterdam 25-27/5/ 2008. Abstract book.
3. ***Kalomenidis I***. Management of malignant pleural disease: overview. Approach to pleural cancer: state-of-the-art. European School of Oncology. Athens 7-8/5/2009. Abstract book.